Document is current

Any future updates will be listed below

Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States

Crossref DOI link: https://doi.org/10.1007/s40121-021-00583-8

Published Online: 2022-01-16

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark